Pregnant Women Left Out of 99% of UK Clinical Trial Applications, New Analysis Reveals

Pregnant women are routinely advised to exercise caution when taking medication, but doctors do not always have sufficient research to determine which treatments are safe for expectant mothers and their unborn babies. An analysis has highlighted the scale of this evidence gap, finding that only 1.1% of UK clinical trial applications submitted between February 2019 and October 2023 proposed including pregnant women.
The findings have renewed concerns about women's representation in medical research, particularly during pregnancy and breastfeeding, when physiological changes can affect how medicines work and the risks they may pose.
The Medicines and Healthcare products Regulatory Agency (MHRA) examined 4,616 clinical trial applications submitted between February 2019 and October 2023. Its analysis found that only 1.1% proposed including pregnant women, while 0.6% proposed including breastfeeding women. This means that approximately 98.9% of the applications did not indicate plans to include pregnant participants.
The findings highlight a significant gap in the evidence available to healthcare professionals when prescribing medicines to pregnant and breastfeeding women.
Why Pregnant Women Need Better Representation in Medical Research
Excluding pregnant women from clinical trials can make it difficult to establish how medicines affect them and their babies. Pregnancy brings physiological changes that can influence how the body absorbs, processes and responds to medication.
Consequently, treatments that have been adequately studied in the general population may not have equally reliable safety and effectiveness data for pregnant women.
This creates a difficult situation for expectant mothers who need medication to manage existing health conditions or treat infections and other illnesses. Without sufficient clinical evidence, some women may avoid potentially beneficial treatments, while others may continue taking medication without clear information about its risks.
The problem also extends to breastfeeding. The MHRA found that just 0.6% of clinical trials included breastfeeding women, leaving substantial uncertainty about how certain medicines may affect breast milk and nursing infants.
The British Pharmacological Society has previously highlighted the importance of addressing these gaps. According to the organisation, more than 80% of women in the UK take at least one medication during pregnancy or breastfeeding.
MHRA Launches Programme to Address Women's Health Research Gaps
In response to longstanding inequalities in medical research, the MHRA launched its Women's Health Programme on 16 November. The initiative aims to improve the evidence available on medicines and medical devices, particularly where their safety and effectiveness may differ between men and women.
The programme will bring together patients, researchers, healthcare professionals and pharmaceutical companies to encourage more inclusive research and improve understanding of women's healthcare needs.
One of its priorities is to strengthen evidence generation during pregnancy and breastfeeding through clinical trials, preclinical research and post-marketing surveillance. The regulator also plans to develop clearer guidance encouraging researchers and pharmaceutical companies to consider including these populations in clinical development.
Additionally, the MHRA intends to improve how information about medication risks and benefits is communicated to pregnant and breastfeeding women, helping them make informed treatment decisions alongside healthcare professionals.
Women Remain Underrepresented Across Clinical Research
The findings also highlight broader inequalities in medical research. Although women account for approximately 51% of the UK population, their healthcare needs have historically received insufficient attention in clinical development.
The MHRA's analysis found that 33.1% of clinical trial applications submitted between 2019 and 2023 proposed including women of childbearing potential. Although 90% of trials included both sexes, male-only studies were more common than female-only research.
The consequences extend beyond pregnancy-related healthcare. Conditions such as endometriosis, menstrual disorders and menopause continue to face research and treatment gaps, while some diseases affect women differently or disproportionately.
The MHRA's programme seeks to address these inequalities throughout women's lives, rather than focusing exclusively on reproductive health.
Ultimately, improving women's representation in clinical research could help doctors make better-informed treatment decisions and ensure medicines are evaluated against the needs of the people who use them.